Re-testing for Chlamydia trachomatis Infection in Massachusetts Family Planning Clinics Marie E. Caggiano, William G. Dumas, Thomas E. Bertrand, Katherine.

Slides:



Advertisements
Similar presentations
© March, In Their Own Right, 2002The Alan Guttmacher Institute (AGI) Why Worry About Men? Addressing mens sexual and reproductive health will help.
Advertisements

St Marys Hospital Ingrid V. Bassett, MD, MPH Massachusetts General Hospital Harvard Medical School May 25, 2010 Who Starts ART in Durban, South Africa?
Texas HIV Perinatal Program Jenny R. McFarlane Texas Dept State Health Services HIV/STD Prevention Services Group Field Operations Team Leader
Expedited Partner Therapy (EPT) for Gonorrhea & Chlamydial Infection
Northern Health Region, Virginia HIV/AIDS and STD Trends Data through 2006.
National Center for State Courts VCCJA Baseline Recidivism Study Fred Cheesman, Ph.D. Tara Kunkel, MSW The National Center for State Courts August 16,
Identifying likely syphilis transmitters: Implications for control & evaluation* Stuart M Berman, MD, ScM Division of STD Prevention CDC, Atlanta, GA *Awaiting.
Recommendations for STD Clinical Preventive Services for Persons Living with HIV/AIDS.
Sexually Transmitted Disease Surveillance 2012 Division of STD Prevention 2012 Data.
The burden of repeat Chlamydia trachomatis infection in young women in New York City Klingler E 1, Pathela P 1, Cordova D 1,2, Blank S 1,2, Schillinger.
HIV Mortality in Florida 2011 Florida Department of Health HIV/AIDS & Hepatitis Program Death data as of 07/12/2012 Created: 07/31/12 Revision: 10/10/12.
Repeat Infections among Adolescents and Young Adults: Findings From Philadelphia STD Clinics Nicole Liddon, PhD 1 Michael Eberhart, BS 2 Jami Leichliter,
Assessment of Chlamydia Rescreening Practices Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.
How to Measure the Effectiveness of the IPP (and all the CT Screening being done)? **Reduce Infertility** Ultimate Goal Reduce PID Reduce Chlamydia Prevalence.
Innovative Approaches to Screen School Populations for Sexually Transmitted Infections Paritosh Kaul, MD Douglas B Richardson Gerrit Bruintjes Cornelis.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Revision of Region II IPP Screening Criteria May 16, 2007 Region II IPP Advisory Committee Meeting Cicatelli Associates Inc. New York City.
Epidemiology of Chlamydia in the United States Debra J. Mosure, Ph.D. Division of STD Prevention Centers for Disease Control and Prevention March 8, 2004.
Repeat Chlamydial Infections in Region III Family Planning Clinics: Implications for Screening Programs Pamela G. Nathanson, Family Planning Council, Inc.
Chlamydia Sexually Transmitted Disease Surveillance 2000 Division of STD Prevention.
Noreen Clark, PhD Molly Gong, MD Melissa Valerio, MPH Sijian Wang, BS Xihong Lin, PhD William Bria, MD Timothy Johnson, MD University of Michigan School.
Chlamydia Sexually Transmitted Disease Surveillance 2008 Division of STD Prevention.
Risk factors for Incident Trichomonas vaginalis among Women Recruited in RESPECT-2, an HIV Prevention Trial D Helms 1, D Mosure 1, T Peterman 1, C Metcalf.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
STD Knowledge and Practices of New York City Providers Meighan E. Rogers, MPH Bureau of STD Control, NYC DOHMH Region II IPP Meeting, May 31-June 1, 2006.
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
Analysis of Chlamydia Re-testing Rates Massachusetts Family Planning Update.
Healthy Kansans living in safe and sustainable environments.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.
RTI International is a trade name of Research Triangle Institute Untreated chlamydial infection among adolescents and young adults in Baltimore,
Re-Screening of CT Positive Clients in Region X IPP, Goldenkranz S., 1 Fine D. 1 1 Center for Health Training 2010 CDC STD Prevention Meeting,
Sexually Transmitted Disease (STD) Surveillance Report, 2009 Minnesota Department of Health STD Surveillance System Minnesota Department of Health STD.
Faiza Ali MD, Ericka Hayes MD, Gaurav Kaushik MPH, Nicole Carr RN, Katie Plax MD Washington University School Of Medicine Department of Pediatrics.
Sexually Transmitted Infections Mysheika Williams Roberts, MD, MPH Medical Director Assistant Health Commissioner Columbus.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
The Obstetric Implications of Diabetes & Diabesity in Malaysia G MUNISWARAN OBSTETRICIAN & GYNAECOLOGIST HOSPITAL RAJA PERMAISURI BAINUN, IPOH.
“The African American Prostate Cancer Crisis in Numbers”
Lower Hudson Valley Perinatal Network Serving Dutchess, Putnam, Rockland & Westchester Counties Presented at the Quarterly Education & Networking Conference.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 1998 Division of STD Prevention.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2007 Division of STD Prevention.
BASELINE ASSESSMENT OF CHLAMYDIA REINFECTION IN REGION VIII FAMILY PLANNING CLINICS FOR Hamby, Y, JSI Research & Training Institute Donovan,
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 1999 Division of STD Prevention.
Chlamydia: Reported Cases, Rates, and Screening in Midwest States Tandra R. Gordon, M.S., 1 Brian C. Gordon, PhD, 2 and Lori W. Turner, PhD 2 Southern.
Predicting Nurse Practitioners’ Intentions and Behaviors to Perform Routine HIV Screening Jodi L. Sutherland, PhD, RN Gale A. Spencer, PhD, RN Binghamton.
Jessica Carag MS Candidate Public Health Microbiology & Emerging Infectious Diseases Milken Institute School of Public Health The George Washington University.
STD’s in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2001 Division of STD Prevention.
Chlamydia screening Is it worth it? Dr. Phillip Hay Reader in Sexual Health & HIV Medicine St. George’s, University of London.
Focus Area 25 Sexually Transmitted Diseases Progress Review July 21, 2004.
NYC DOHMH BSTDC School-Based Education, Screening and Treatment Pilot Program Meighan Rogers, MPH Bureau of STD Control, NYC DOHMH Region II IPP Meeting,
Region I IPP Data Presentation Advisory Board Meeting June 2008 Wells, ME.
STDs in Racial and Ethnic Minorities Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.
STDs in Women and Infants Sexually Transmitted Disease Surveillance 2008 Division of STD Prevention.
Sexually Transmitted Disease Surveillance 2011 Division of STD Prevention.
STDs in Women and Infants Sexually Transmitted Disease Surveillance 2007 Division of STD Prevention.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2005 Division of STD Prevention.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2004 Division of STD Prevention.
IPP Infrastructure Measures of Effectiveness: Preliminary Data and Next Steps Kelly Morrison Opdyke, MPH Region II Infertility Prevention Project Cicatelli.
Is it possible to predict New Onset Diabetes After Transplantation (NODAT) in renal recipients using epidemiological data alone? Background NODAT is an.
Lower Mammography Use is Associated with the Geographic Clustering of Late-stage Breast Cancer in Saint Louis City Min Lian, Donna B. Jeffe, Mario Schootman.
Cervical Cancer Screening Guidelines and Rates of Chlamydia Screening Allison Ursu, MD Ananda Sen, PhD Mack Ruffin, MD, MPH April 27, 2015 Department of.
Demographic and Behavioral Differences between Latino and non-Latino Patients Attending Baltimore City STD Clinics, Renee M. Gindi 1, Kathleen.
*Aminu Maryam and Ejiogu C. Nkechi
Pediatrics HIV/AIDS and PMTCT research in Barbados: lessons learned for monitoring the epidemic and evaluating the interventions.   ALOK KUMAR, MD. Lecturer.
It's not what you know, but who you know: Risk factors for re-infection in the Philadelphia High School STD Screening Program Jennifer Beck, MPH APHA.
Martin Goldberg1, Daniel R. Newman2, TA Peterman2,
Poster WP41; Contact: David A. Katz,
M Javanbakht, S Guerry, LV Smith, P Kerndt
Forest plot of various sensitivity analyses of the risk for pelvic inflammatory disease (PID), ectopic pregnancy and tubal factor infertility (TFI) between.
Presentation transcript:

Re-testing for Chlamydia trachomatis Infection in Massachusetts Family Planning Clinics Marie E. Caggiano, William G. Dumas, Thomas E. Bertrand, Katherine K. Hsu, Sylvie Ratelle

Abstract Background Because a high prevalence of chlamydia re-infection has been observed in women following treatment for chlamydia infection, the CDC has recommended re-testing of all women approximately 3 months after treatment for chlamydia infection. Little is known about factors influencing a womans return for re-testing. Objective To examine factors associated with chlamydia re-testing after treatment for chlamydia infection. Methods A case was defined by first positive chlamydia test in a woman seen between 1/1/05-12/31/05 at one of 8 Massachusetts family planning organizations. Data available for review included age at diagnosis, clinic organization, race/ethnicity, and history of prior chlamydia infection. Multivariate logistic regression was performed to identify factors associated with chlamydia retesting 3-<12 months after the initial positive test. Results Of 402 chlamydia cases in women identified during the study period, 116 (29%) had re-testing within years old. The two clinic organizations handling highest number of chlamydia infections re-tested 62/161 (39%), versus 9/56 (16%) in two clinic organizations with lowest number. Younger age (OR 1.8, 95% CI ) and highest number (OR 3.3, CI ) were associated with retesting in a logistic regression model including age, race/ethnicity, clinic organization, and prior history of chlamydia infection. No significant associations with re-testing were found with race/ethnicity or prior history of chlamydia infection. Conclusions Repeat chlamydia infection was common in women re-tested for chlamydia 3-<12 months after incident chlamydia infection. Younger age and certain clinic organizations were associated with greater chlamydia re- testing amongst women seen at Massachusetts family planning organizations.

Background Recurrent or persistent chlamydia infection occurs in 10-15% of cases 1 –Some studies report rates as high as 15-38% 2,3 –Most often related to re-exposure from an untreated sexual partner 4 –Associated with increased rates of pelvic inflammatory disease and hospitalization for related complications 5 Follow-up screening recommended since 1996 for all women diagnosed with chlamydia infection 1 –Ideally performed 3-4 months after completion of antibiotic treatment –Offered at any visit occurring 3-12 months after treatment –Differentiated from test of cure (which is done 3-4 weeks following treatment and indicated only in specific circumstances) Risk factors associated with recurrent infection have been well studied, but little is known about factors that influence attendance for follow-up screening

Methods (1) Data abstraction –Review of records of women tested at Massachusetts family planning clinics participating in the Infertility Prevention Project (IPP) –Case defined by positive chlamydia test (strand displacement assay, BD Probetec ET; Becton Dickinson, Sparks, MD) between 01/01/05 to 12/31/05 –Each case reviewed for age at initial diagnosis, clinic site, race/ethnicity, history of prior chlamydia infection reported in Massachusetts, and chlamydia testing 3-12 months after initial diagnosis Age categorized into two groups –>18 years –< 18 years Race/ethnicity categorized into four groups –White, non-Hispanic –Black non-Hispanic –Hispanic –Other, non-Hispanic –Unknown ethnicity Clinics categorized based on volume of positive chlamydia tests –8 clinic organizations categorized into 4 sub-groups based on number of positive chlamydia tests handled

Methods (2) Data analysis –Bivariate analysis and multivariate logistic regression used to examine factors associated with re-testing within 3-12 months of initial diagnosis –SAS version 9.1 (SAS Institute, Inc., Cary, NC) utilized –Waiver granted by Massachusetts Department of Public Health (MDPH) Human Research Review Committee (HRRC)

Figure 1 Proportion of Women Re-tested for Chlamydia Within 3-12 Months of Initial Diagnosis N=402

Figure 2 Proportion of Positives in Women Re-tested for Chlamydia Within 3-12 Months of Initial Diagnosis N=116

Figure 3a: Percent of Women Re-tested for Chlamydia by Age Women < 18 yearsWomen > 18 years Percent Re-tested

Figure 3b: Percent of Women Re-tested for Chlamydia by Race/Ethnicity Percent Re-tested

Figure 3c: Percent of Women Re-tested for Chlamydia by History of Prior Chlamydia Infection HistoryNo history Percent Re-tested

Figure 3d: Percent of Women Re-tested for Chlamydia by Volume of Positives at Clinic Site Percent Re-tested Clinic Sites by Volume of Positive Chlamydia Tests

Table 1. Association Between Variables and Chlamydia Re-testing 3-12 Months After Initial Diagnosis *Odds ratios adjusted for age category, history of prior infection, race/ethnicity, and volume of testing at clinic site

Conclusions Among women tested for chlamydia at Massachusetts family planning clinics, approximately 29% were re-tested within 3-12 months of initial diagnosis –25% of women re-tested for chlamydia had recurrent infection Age < 18 years and highest clinic positivity were associated with greater rates of re-testing

Limitations Findings based on retrospective record review with only a limited number of factors available for analysis

Implications Further study is needed to identify additional factors that influence re- testing rates and examine strategies for increasing rates of re-testing In 2006, MDPH began a monthly report-back system to notify clinics of positives and facilitate call backs for re-testing –Analyses underway to evaluate effectiveness of this intervention

References 1.Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, MMWR 2006;55(RR-11): Xu et al. Repeat chlamydia trachomatis infection in women: Analysis through a surveillance case registry in Washington state Am J Epidemiol 2000;152: Blythe et al. Recurrent genitourinary chlamydial infections in sexually active female adolescents. J Pediatr 1992;121: Peterman et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: A case for re- screening. Ann Intern Med 2006;145: Hillis et al. Recurrent chlamydial infections increase risk of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997;176:

VariableWomen Re- tested N=116 ( 29%) Women Not re- tested N=286 Total to N= 402 Women Re-tested N=148 ( 43%) Women Not Re- tested N= 192 Total to N= 340 Age >18 years73 ( 25%) ( 39%) <18 years43 ( 41%) ( 51%)56115 Race/ethnicity White non- Hispanic 50 (26%) ( 48%) 73 ( 46%) ( 46%) Black non- Hispanic 21 ( 35%) 3960 ( 15%) 35 ( 43%) 4681 ( 24%) Hispanic26 (36%)4672 ( 18%)17 ( 37%)2946 ( 13%) Other non- Hispanic 4 ( 20%) 1620 ( 5%) 7 ( 53%) 613 ( 4%) Unknown15 ( 37%)4257 ( 14%)16 ( 37%)2743 ( 13%)